摘要
目的:探讨噻托溴铵联合布地奈德福莫特罗联合治疗哮喘-慢阻肺重叠综合征(ACOS)的临床效果,研究对患者内皮素(ET-1)和可溶性细胞间黏附分子(sICAM-1)水平的影响。方法:选取2017年1月-2020年1月重庆市江北区中医院肺病科接诊的96例ACOS患者。按照双盲法分组标准分为对照组和治疗组,各48例。对照组给予噻托溴铵单药治疗,治疗组在对照组单药治疗基础上联合布地奈德福莫特罗治疗。比较两组FeNO、肺功能指标、CAT评分和ACT评分及内皮细胞功能指标水平,分析并发症发生情况。结果:治疗后,治疗组FEV1和IC/TLC水平均高于对照组,FeNO和RV-TLC水平低于对照组(P<0.05)。治疗后,两组ET-1和sICAM-1水平均较治疗前下降,治疗组低于对照组(P<0.05)。治疗后,两组CAT评分均较治疗前降低,ACT评分均较治疗前升高,治疗组CAT评分低于对照组,治疗组ACT评分高于对照组(P<0.05)。治疗组并发症发生率(4.17%)明显低于对照组的16.67%(P<0.05)。结论:在噻托溴铵单药治疗基础上,联合布地奈德福莫特罗治疗的ACOS患者FeNO水平下降,肺功能提高,血管内皮功能显著改善,临床症状缓解,并发症减少,安全性提升。
Objective:To investigate the clinical effect of Tiotropium Bromide combined with Budesonide Formoterol in the treatment of asthma-COPD overlap syndrome(ACOS),and to study the influence on the levels of endothelin-1(ET-1)and soluble intercellular adhesion molecule-1(sICAM-1).Method:A total of 96 ACOS patients admitted to the pulmonary department of Chongqing Jiangbei Hospital of Traditional Chinese Medicine from January 2017 to January 2020 were selected.They were divided into the control group and the treatment group according to the double-blind grouping criteria,48 cases in each group.The control group was given Tiotropium Bromide single drug treatment,the treatment group was treated with Budesonide Formoterol on the basis of single drug treatment in the control group.The levels of FeNO,pulmonary function indexes,CAT score,ACT score and endothelial cell function indexes were compared between the two groups.Result:After treatment,the levels of FEV1 and IC/TLC in the treatment group were higher than those in the control group,while the levels of FeNO and RV-TLC in the treatment group were lower than those in the control group(P<0.05).After treatment,the levels of ET-1 and sICAM-1 of the two groups were lower than those before treatment(P<0.05),those in the treatment group were lower than those in the control group(P<0.05).After treatment,the CAT scores of the two groups were lower than those before treatment,the ACT scores were higher than those before treatment,the CAT score of the treatment group was lower than that of the control group,and the ACT score of the treatment group was higher than that of the control group(P<0.05).The incidence of complications of treatment group(4.17%)was significantly lower than 16.67%of the control group(P<0.05).The total incidence of complications in the treatment group(4.17%)was significantly lower than that in the control group 16.67%(P<0.05).Conclusion:On the basis of Tiotropium Bromide monotherapy,ACOS patients who are combined with Budesonide Formoterol treatment,FeNO level
作者
何宗林
颜田赅
HE Zonglin;YAN Tiangai(Chongqing Jiangbei Hospital of Traditional Chinese Medicine,Chongqing 400020,China;不详)
出处
《中外医学研究》
2021年第12期127-129,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
